BioCentury This Week
Episodes
Ep. 144 - Alnylam's IRA Pause, Plus Argenx & Accumulus
31 Oct 2022
Contributed by Lukas
Biopharmas and investors have been warning of the Inflation Reduction Act’s potential to hurt patients — concerns that had been theoretical until ...
Ep. 143 - East-West Summit Preview
28 Oct 2022
Contributed by Lukas
McKinsey’s Franck Le Deu and BayHelix’s Guo-Liang Yu join the BioCentury This Week podcast to discuss globalization and cross-border innovation in...
Ep. 142 - Lundbeck, Biogen, Biden & Biomanufacturing, Nora Volkow
25 Oct 2022
Contributed by Lukas
A pair of neurology companies are in the spotlight on the latest edition of the BioCentury This Week podcast. BioCentury’s editors assess how Lundbe...
Ep. 141 - Neoantigen Vaccines, Drug Pricing, U.S.-China & U.K. Turmoil
17 Oct 2022
Contributed by Lukas
On the latest BioCentury This Week podcast, Senior Editor Karen Tkach Tuzman surveys the landscape of neoantigen cancer vaccines, touching on what’s...
Ep. 140 - Turbulence at BIO, Plus 4Q Preview & the Distillery
11 Oct 2022
Contributed by Lukas
On the latest BioCentury This Week podcast, Washington Editor Steve Usdin details the circumstances leading up to Michelle McMurry-Heath’s resignati...
Ep. 139 - Wins in Neurodegeneration, U.S.-China & Life Science Cares
04 Oct 2022
Contributed by Lukas
The neurodegeneration field had two big wins with even bigger implications for the future of Alzheimer’s disease and ALSs, Executive Editor Selina K...
Ep. 138 - FDA User Fee Endgame, East-West Summit & Biogen
27 Sep 2022
Contributed by Lukas
Everything’s at stake for FDA as user fee legislation approaches a critical deadline this week, Washington Editor Steve Usdin says on the latest epi...
Ep. 137 - Intellia's Data, IRA's Orphan Impact, CFIUS Order
19 Sep 2022
Contributed by Lukas
A year after it reported its first clinical data showing CRISPR-based gene editing may live up to its promise, Intellia has provided evidence for the ...
Ep. 136 - IRA, KRAS & ESMO
13 Sep 2022
Contributed by Lukas
Biopharma executives and investors are bracing for the impact of the newly passed Inflation Reduction Act. On the latest BioCentury This Week podcast,...
Ep 135 Pt. 5 - A Portrait of Biopharma's New Leaders
02 Sep 2022
Contributed by Lukas
Digital fluency, the imperative to have an impact on society and an eagerness to make change now, not in future decades, mark the future leaders of th...
Ep 135 Pt. 4 - Filling Biopharma's Talent Pipeline
01 Sep 2022
Contributed by Lukas
The need to recruit and train regulators is acute in developed as well as low- and middle-income countries, BioCentury Washington Editor Steve Usdin s...
Ep 135 Pt. 3 - Rising Leaders & the VC View on Talent
31 Aug 2022
Contributed by Lukas
Solving the biopharma industry’s management crunch will require today’s leaders to open their networks, and provide more leadership opportunities ...
Ep 135 Pt. 2 - CEOs in the Spotlight. Plus: Women Leaders, DEI
30 Aug 2022
Contributed by Lukas
The past two years have forced a reckoning for CEOs throughout the biopharma industry that will shape the next generation of success stories. On the s...
Ep 135 Pt. 1 - Back to School 2022 Overview
29 Aug 2022
Contributed by Lukas
BioCentury’s 30th annual Back to School edition focuses on talent: where to find talent and how to nurture it. It’s a special Back to School packa...
Ep. 134 - Preclinical Deal Making, Bluebird's Approval & Epigenome Editing
22 Aug 2022
Contributed by Lukas
Despite public market investors shying away from preclinical companies amid biotech’s bear market, large biopharmas have ramped up their deal making...
Ep. 133 - Financing Thaw? Plus: Protein Design & China Audits
16 Aug 2022
Contributed by Lukas
A flurry of follow-on financings last week suggests a receptive market for companies with recent catalysts, BioCentury’s Paul Bonanos says on the la...
Ep. 132 - M&A & Data: recipe for a rebound?
09 Aug 2022
Contributed by Lukas
The proposed $5.4 billion takeout of sickle cell company Global Blood Therapeutics by Pfizer is the latest sign of life in biotech M&A, BioCentury...
Ep. 131 - Seagen, New Modalities & Structure
02 Aug 2022
Contributed by Lukas
Acquisition target Seagen has carved out such a differentiated portfolio of antibody-drug candidates that the company may not see much direct competit...
Ep. 130 - Steady as a Roche. Plus: Washington Turbulence
25 Jul 2022
Contributed by Lukas
As Severin Schwan’s steady hand on the tiller of Roche passes to another insider, BioCentury’s podcast team examines how initiatives during the ou...
Ep. 129 - Burr Bill, Novartis Makeover, ALS Update
19 Jul 2022
Contributed by Lukas
Sen. Richard Burr’s new approach to a critical medical products user fee bill funding FDA must be taken seriously because the clock is ticking, and ...
Ep. 128 - Financial Markets Forecast, AAV Toxicity & Drug Pricing
12 Jul 2022
Contributed by Lukas
Even with signs that the biotech winter may be starting to thaw, buysiders continue to expect more near-term pain for the sector as consolidation cont...
Ep. 127 - TeneoTwo, Lightspeed, Arch & The Distillery
06 Jul 2022
Contributed by Lukas
AstraZeneca’s takeout of single-asset spinout TeneoTwo for $100 million up front is but the latest payout to shareholders in TeneoBio, who could sta...
Ep. 126 - Growing Galapagos, Plus Abortion & Biopharma
28 Jun 2022
Contributed by Lukas
On the latest BioCentury This Week podcast, a pair of deals demonstrates how Galapagos CEO Paul Stoffels is shifting the Belgian biotech’s strategic...
Ep. 125 - Next Steps for ARPA-H
21 Jun 2022
Contributed by Lukas
On the latest BioCentury This Week podcast, Washington Editor Steve Usdin details how the Advanced Research Projects Agency for Health is taking shape...
Ep. 124 - CRISPR's High Bar, Private Equity Inroads and the Distillery
13 Jun 2022
Contributed by Lukas
Stellar data for Vertex Pharmaceuticals and CRISPR Therapeutics could set a high bar for the next generation of gene editing players to beat in β tha...
Ep. 123 - Fixing FDA's Broken Advisory Panels
08 Jun 2022
Contributed by Lukas
Reach us by sending a text
Ep. 122 - ASCO's Advances & Fixes for FDA's AdComms
07 Jun 2022
Contributed by Lukas
Stellar ASCO data for Enhertu show how there’s “massive ground” that can still be covered and improved upon by applying new modalities against...
Ep. 121 - ASCO, CRISPR IP & CStone
01 Jun 2022
Contributed by Lukas
The latest data cut for KRAS G12C inhibitor adagrasib from Mirati Therapeutics underwhelmed investors. On the latest BioCentury This Week podcast, Bio...
Ep. 120 - Next-gen NK cells, Plus Woodcock & BMS’s Russian Withdrawal
23 May 2022
Contributed by Lukas
On the latest BioCentury This Week podcast, BioCentury’s editors explore how biotechs are turning to tumor targeting, IL-15 expression and alternate...
Ep. 119 - Bio€quity Recap, Part 2
19 May 2022
Contributed by Lukas
Ensuring that a biotech reaches its key inflection points as effectively as possible during the ongoing capital crunch affects a company across the bo...
Ep. 118 - Bio€quity Recap, Part 1
18 May 2022
Contributed by Lukas
Even as industry is facing a global talent crunch, Europe’s biotechs have it better than ever, Medicxi’s Francesco De Rubertis said on a special e...
Ep. 117 - Sofinnova Partners’ Growth Deal, Plus Distillery on Tap
17 May 2022
Contributed by Lukas
The sale of a minority stake in Sofinnova Partners to PE firm Apollo will allow the European VC to grow while retaining its independence. Fresh off a ...
Ep. 116 - The Road to Bio€quity 2022: Navigating Through Talent & Capital Headwinds
12 May 2022
Contributed by Lukas
Industry’s dueling headwinds of capital and talent are the focus of this year’s Bio€quity Europe meeting, and in a special episode of BioCentury...
Ep. 115 - FDA Reform on Deck, Plus Translation at Howard
10 May 2022
Contributed by Lukas
The House Energy & Commerce Committee has a bipartisan deal on reauthorizing FDA user fees that sets the parameters for FDA reforms, including enh...
Ep. 114 - Hutchmed Setback, FDA in Focus, HilleVax's IPO
03 May 2022
Contributed by Lukas
Chinese biotechs face regulatory delays for their therapies due to pandemic-related barriers to inspections by Western regulators and FDA’s reluctan...
Ep. 113 - Nkarta’s Breakthrough, Hatch’s Legacy & Shanghai’s Lockdown
26 Apr 2022
Contributed by Lukas
The first clinical data from Nkarta’s CAR natural killer cell platform add to the growing evidence that a CAR may provide the efficacy boost NK cell...
Ep. 112 - Digesting DDR Data; Plus Sharpless’ Legacy, McKinsey’s Conflicts
19 Apr 2022
Contributed by Lukas
Long-awaited proof of concept for AstraZeneca’s PARP-1-selective therapy opens the door to combination strategies previously limited by hematopoieti...
Ep. 111 - Seeking Green Shoots Amid Biotech’s Gloom
14 Apr 2022
Contributed by Lukas
Positive fund flows and modestly better performance by biotech indexes offer hints that the beginnings of a recovery could be possible in the near ter...
Ep. 110 - Aduhelm’s Lessons, Plus Distillery Discoveries, Rare Disease Innovation
12 Apr 2022
Contributed by Lukas
BioCentury's editors break down CMS’s final coverage decision on amyloid mAbs for Alzheimer’s disease, focusing on what the lessons are from ...
Ep. 109 - What's Next for Novartis? Plus: AACR, Merck KGaA
05 Apr 2022
Contributed by Lukas
Novartis is prioritizing “high-value,” multibillion-dollar assets as it reorganizes. On the latest BioCentury This Week podcast, BioCentury’s ed...
Ep. 108 - AACR Preview for CAR Ts in Solid Tumors; Plus FDA Weighs in on Data for ALS Ad Com
29 Mar 2022
Contributed by Lukas
AACR is just around the corner, and new data being presented at the conference details how stakeholders are improving the specificity of CAR T therapi...
Ep. 107 - A Tale of Two Targets: LAG3, IL-2; Plus Alternatives to Cash Up
22 Mar 2022
Contributed by Lukas
The importance of FDA’s approval of Bristol Myers' LAG3 inhibitor Opdualag nivolumab/relatlimab for melanoma, the pharma’s disruptive marketi...
Ep. 106 - China's C-suite Hears FDA, Plus AACR, ARPA-H
15 Mar 2022
Contributed by Lukas
Chinese immuno-oncology companies are changing how they interact with FDA as they seek approval of PD-1 programs. On this episode of BioCentury This W...
Ep. 105 - War Pulls Biotech to Ukraine, Out of Russia
08 Mar 2022
Contributed by Lukas
War Pulls Biotech to Ukraine, Out of Russia: BioCentury's editors look at how the worsening crisis in Ukraine is affecting the global life scienc...
Ep. 104 - Biotech Shows Support for Ukraine, Plus Latest Intellia Data
01 Mar 2022
Contributed by Lukas
Industry leaders have vowed to disengage with Russia until it stops its invasion of Ukraine and respects its neighbor’s sovereignty. What's the...
Ep. 103 - Califf’s Priorities for Second Stint as FDA Commissioner
23 Feb 2022
Contributed by Lukas
Newly confirmed FDA commissioner Rob Califf will be prioritizing a proactive communications strategy, including combating misinformation about science...
Ep. 102 - What FDA's Tyvyt Precedent Means for China; plus Translational Trendspotting
15 Feb 2022
Contributed by Lukas
FDA and its advisory panel of oncology experts have repudiated the use of China-only data for regulatory submissions in the U.S. How will China's...
Ep. 101 - Of Biotech Bears, Pazdur & PDUFA
08 Feb 2022
Contributed by Lukas
Weathering the bear market. Oncology chief’s change in thinking on PD-1 therapies. Plus BioCentury’s 2021 innovative start-ups. This week’s podc...
Ep. 100 - Capital markets check in; plus Belgium’s prodigal son returns
01 Feb 2022
Contributed by Lukas
This week’s podcast is sponsored by ICON.Reach us by sending a text
Ep. 99 - Introducing The BioCentury Show, Plus Califf, COVID and GSK
25 Jan 2022
Contributed by Lukas
BioCentury’s new in-depth conversational series launches with Scott Gottlieb as debut guest. This week’s podcast is sponsored by ICON.Reach us by ...
Ep. 98 - Bargain Hunting in a Rocky Market, plus Advantage, CMS
19 Jan 2022
Contributed by Lukas
Part two of BioCentury’s 2022 Financial Markets Preview, access to Alzheimer’s mAbs, and translational highlights from the Distillery. This week’...
Ep. 97 - Buysiders' Picks, plus JPM22 roundup
11 Jan 2022
Contributed by Lukas
Reach us by sending a text
Ep. 96 - Aduhelm, Pazdur, Pharma Digital & '21 Wrap
21 Dec 2021
Contributed by Lukas
Reach us by sending a text
Ep. 95 - ASH's New Targets, Avistone & Washington Update
14 Dec 2021
Contributed by Lukas
Reach us by sending a text
Ep. 94 - Woodcock's To-Do List, Maraganore's Takeaways & the Distillery
07 Dec 2021
Contributed by Lukas
Reach us by sending a text
Ep. 93 - Omicron's Open Questions, Plus the Business Case for Ultra-rare Diseases
30 Nov 2021
Contributed by Lukas
Reach us by sending a text
Ep. 92 - Biogen’s R&D decision, previewing TIGIT & China Summit highlights
22 Nov 2021
Contributed by Lukas
Reach us by sending a text
Ep. 91 - China Summit Highlights: Day 2
18 Nov 2021
Contributed by Lukas
Reach us by sending a text
Ep. 90 - China Summit Highlights: Day 1
17 Nov 2021
Contributed by Lukas
Reach us by sending a text
Ep. 89 - Califf's Passions, RWE in China & LSP Rising
16 Nov 2021
Contributed by Lukas
Reach us by sending a text
Ep. 88 - China Summit Preview: The Bridge to Innovation
10 Nov 2021
Contributed by Lukas
Reach us by sending a text
Ep. 87 - Digesting Drug Pricing, Plus Access in ALS
09 Nov 2021
Contributed by Lukas
Reach us by sending a text
Ep. 86 - Woodcock's Legacy, Plus Frazier, Bain & the Distillery
02 Nov 2021
Contributed by Lukas
Reach us by sending a text
Ep. 85 - What's Next for CRISPR & Gene Therapy, Plus China Summit Preview
26 Oct 2021
Contributed by Lukas
Reach us by sending a text
Ep. 84 - Why Gene Therapy's Bad Year Is a Speed Bump, Not a Dead End
22 Oct 2021
Contributed by Lukas
Reach us by sending a text
Ep. 83 - Assessing Biogen’s ALS Miss, Plus Califf on Deck
18 Oct 2021
Contributed by Lukas
Reach us by sending a text
Ep. 82 - 4Q Markets Preview, Plus the Future of NIH
12 Oct 2021
Contributed by Lukas
Reach us by sending a text
Ep. 81 - Merck & the State of M&A, Plus Novartis CEO's Call to Action
05 Oct 2021
Contributed by Lukas
Reach us by sending a text
Ep. 80 - Hong Kong Rising, Plus Varmus' POV & Biden's FDA Choice
28 Sep 2021
Contributed by Lukas
Reach us by sending a text
Ep. 79 - ESMO, Jeito & the Latest from Washington
21 Sep 2021
Contributed by Lukas
Reach us by sending a text
Ep. 78 - Remembering Fred Frank, Lisa Raines, Plus CRISPR, Washington Updates
14 Sep 2021
Contributed by Lukas
Reach us by sending a text
Ep. 77 - Back to School Spotlight & Pressures on FDA
04 Sep 2021
Contributed by Lukas
Reach us by sending a text
Ep 76 Pt. 4 - Modifying Access for Accelerated Approvals
01 Sep 2021
Contributed by Lukas
Reach us by sending a text
Ep 76 Pt. 3 - Delivering the Evidence for Accelerated Approval
01 Sep 2021
Contributed by Lukas
Reach us by sending a text
Ep 76 Pt. 2 - Standards of Evidence for Accelerated Approval
30 Aug 2021
Contributed by Lukas
Reach us by sending a text
Ep 76 Pt. 1 - Accelerated Approval's Big Picture
30 Aug 2021
Contributed by Lukas
Reach us by sending a text
Ep. 75 - Back to School Preview, plus Pfizer Eats Trillium
24 Aug 2021
Contributed by Lukas
Reach us by sending a text
Ep. 74 - Vertex's Road Map & Innovation in MS
16 Aug 2021
Contributed by Lukas
Reach us by sending a text
Ep. 73 - Next Up in COVID with Otello Stampacchia and Umer Raffat
13 Aug 2021
Contributed by Lukas
Reach us by sending a text
Ep. 72 - Modality Matters: M&A Heats Up, Galbraith Maps AZ's BD
09 Aug 2021
Contributed by Lukas
Reach us by sending a text
Ep. 71 - Lessons from China’s Market Turmoil, Plus Distillery on Tap
03 Aug 2021
Contributed by Lukas
Reach us by sending a text
Ep. 70 - Prepping for China’s IP law with Jones Day’s Tony Chen
29 Jul 2021
Contributed by Lukas
Reach us by sending a text
Ep. 69 - Allaying Aduhelm Concerns, Plus Master Protocols, Arvinas-Pfizer
27 Jul 2021
Contributed by Lukas
Reach us by sending a text
Ep. 68 - Drug Pricing Pressure, Plus European Deal Trends
20 Jul 2021
Contributed by Lukas
Reach us by sending a text
Ep. 67 - Aduhelm: a Tangled Plot; Plus, INTREPID Pandemic Planning
13 Jul 2021
Contributed by Lukas
Reach us by sending a text
Ep. 66 - Biotechs hit 3Q with Coolers Full of Cash; plus Distillery on Tap
06 Jul 2021
Contributed by Lukas
Reach us by sending a text
Ep. 65 - Optimism for Intellia's CRISPR Breakthrough, Concerns about Aduhelm
29 Jun 2021
Contributed by Lukas
Reach us by sending a text
Ep. 64 - Amyloid Analysis: Stress Testing FDA's Logic on Surrogate Endpoint
24 Jun 2021
Contributed by Lukas
Reach us by sending a text
Ep. 63 - Woodcock, Noubar and Genmab’s dealmaking: A BioCentury Podcast
21 Jun 2021
Contributed by Lukas
Reach us by sending a text
Ep. 62 - Reflecting on the Implications of Aduhelm's Approval: A BioCentury Podcast
14 Jun 2021
Contributed by Lukas
Reach us by sending a text
Ep. 61 - Dissecting FDA's Aducanumab Decision
08 Jun 2021
Contributed by Lukas
Reach us by sending a text
Ep. 60 - D-Day for Aducanumab: What's at stake
02 Jun 2021
Contributed by Lukas
Reach us by sending a text
Ep. 59 - KRAS to the Future; plus ARPA-H & EGFR
02 Jun 2021
Contributed by Lukas
Reach us by sending a text
Ep. 58 - LAG3 Before You Leap; plus BEE21, G20 Highlights
24 May 2021
Contributed by Lukas
Reach us by sending a text
Ep. 57 - Financing Scandinavia; plus IP Waivers, Long Covid & AAV Pays
10 May 2021
Contributed by Lukas
Reach us by sending a text
Ep. 56 - FDA’s ODAC Bind; plus NK Cell Engagers and Company Creation in Europe
04 May 2021
Contributed by Lukas
Reach us by sending a text
Ep. 55 - German Plays Deliver on Data, plus Accelerated Approval on Trial
27 Apr 2021
Contributed by Lukas
Reach us by sending a text
Ep. 54 - Patient Groups’ Pandemic Pain; plus Voters’ Rights and Synthetic Lethality
20 Apr 2021
Contributed by Lukas
Reach us by sending a text
Ep. 53 - Competence & Continuity at CDER; plus BIO 3.0, AACR and 2Q Preview
13 Apr 2021
Contributed by Lukas
Reach us by sending a text
Ep. 52 - Memories of John Martin, plus AACR's Hot Targets & Bio€quity Europe Preview
06 Apr 2021
Contributed by Lukas
Reach us by sending a text